Dermatophyte (tinea) infections

Goldstein A, Goldstein B

2018

Topical corticosteroids are not recommended as first line treatment option for dermatophytes. Despite the possibility of accelerating healing time, the combined use of antifungal and corticosteroid products has an increased risk for topical corticosteroid-induced skin atrophy. Therefore, combining the products in treatment introduces patients to an unnecessary risk and side effect that can be avoided by using antifungal products singularly.

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

March 11, 2022

Full Article Yiu Z, Ashcroft D, Evans I, McElhone K, Lunt M, Smith C, Walton S, Murphy R, Reynolds N, Ormerod A, Griffiths C, Warren

Moderate exercise and bright light treatment in overweight and obese individuals

March 11, 2022

Full Article Dunai A, Novak M, Chung S, Kayumov L, Keszei A, Levitan R, Shapiro C Obesity. 2007;15(7):1749-1757. “This randomized, controlled study is the first

Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study

March 11, 2022

Full Article Malanos D Stern R J Am Acad Dermatol. 2007;57(2):231-7. doi:10.1016/j.jaad.2007.04.027 A common fear associated with the use of psoralen plus ultraviolet A (PUVA)

Dermatophyte (tinea) infections

Goldstein A, Goldstein B

Related Posts

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Moderate exercise and bright light treatment in overweight and obese individuals

Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study

CALL 1-800-DAAVLIN OR FILL OUT THE FORM BELOW

CALL 1-800-DAAVLIN OR
FILL OUT THE FORM BELOW